AGA Files for Approval to Market INOmax in the United States

AGA FILES FOR APPROVAL TO MARKET INOmax IN THE UNITED STATES Following its announcement of positive clinical trial results earlier this year, AGA has filed an application with the Food and Drug Administration (FDA) for approval to market INOmax in the United States. AGA is seeking approval to use inhaled nitric oxide, INOmax , for the treatment of hypoxemic respiratory failure in the term and the near-term newborn. Treatment INOmax is based on the discovery that in low concentrations, inhaled nictric oxide acts as a selective pulmonary vasodilator that dilates constricted blood vessels in the lungs without affecting the blood vessels in other parts of the body. The discovery of nitric oxide (NO) as the messenger EDRF (Endothelial Derived Relaxing Factor) was awarded the 1998 Nobel Prize in Physiology or Medicine. Several inhaled nitric oxide related method of use patents owned by Massachusetts General Hospital in the USA have been exclusively licensed to AGA on a worldwide basis. For further information please contact Lars Källsäter, Executive Vice President Division Healthcare, phone +46 8 731 1270 or Maris Sedlenieks, Corporate Vice President Corporate Communications, phone +46 8 731 1050. Lidingö June 18, 1999 AGA Aktiebolag (publ) Corporate Communications ------------------------------------------------------------ Please visit for further information The following files are available for download: